Stock Track | Hims & Hers Health Soars 10.66% in Pre-Market on Novo Nordisk Partnership and FDA's Peptide Regulatory Review

Stock Track

Apr 16

Hims & Hers Health Inc. (HIMS) experienced a significant pre-market surge of 10.66%, continuing its positive momentum from the previous trading session.

The sharp rise appears driven by two major catalysts. First, the company has entered into a partnership with pharmaceutical giant Novo Nordisk, which will authorize the sale of Novo Nordisk's weight-loss drugs on the Hims platform. This marks a significant commercial milestone, expanding Hims' offerings in the high-demand weight management market.

Secondly, U.S. regulators are moving forward with plans to reassess popular peptide treatments. The Food and Drug Administration has scheduled meetings to discuss whether certain pharmacies may be allowed to produce specific peptide substances, which could make these treatments more widely available. Hims & Hers had previously indicated to investors its interest in entering the peptide space, making this regulatory development a positive signal for its future business categories.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/news/1190132675"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1190132675\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1190132675?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-16 16:05","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1190132675","market":"nz","top_or_hot":-1,"title":"Stock Track | Hims & Hers Health Soars 10.66% in Pre-Market on Novo Nordisk Partnership and FDA's Peptide Regulatory Review","media":"Stock Track","content":"<p>Hims & Hers Health Inc. (HIMS) experienced a significant pre-market surge of 10.66%, continuing its positive momentum from the previous trading session.</p><p>The sharp rise appears driven by two major catalysts. First, the company has entered into a partnership with pharmaceutical giant Novo Nordisk, which will authorize the sale of Novo Nordisk's weight-loss drugs on the Hims platform. This marks a significant commercial milestone, expanding Hims' offerings in the high-demand weight management market.</p><p>Secondly, U.S. regulators are moving forward with plans to reassess popular peptide treatments. The Food and Drug Administration has scheduled meetings to discuss whether certain pharmacies may be allowed to produce specific peptide substances, which could make these treatments more widely available. Hims & Hers had previously indicated to investors its interest in entering the peptide space, making this regulatory development a positive signal for its future business categories.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Hims & Hers Health Soars 10.66% in Pre-Market on Novo Nordisk Partnership and FDA's Peptide Regulatory Review</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Hims & Hers Health Soars 10.66% in Pre-Market on Novo Nordisk Partnership and FDA's Peptide Regulatory Review\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-04-16 16:05</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Hims & Hers Health Inc. (HIMS) experienced a significant pre-market surge of 10.66%, continuing its positive momentum from the previous trading session.</p><p>The sharp rise appears driven by two major catalysts. First, the company has entered into a partnership with pharmaceutical giant Novo Nordisk, which will authorize the sale of Novo Nordisk's weight-loss drugs on the Hims platform. This marks a significant commercial milestone, expanding Hims' offerings in the high-demand weight management market.</p><p>Secondly, U.S. regulators are moving forward with plans to reassess popular peptide treatments. The Food and Drug Administration has scheduled meetings to discuss whether certain pharmacies may be allowed to produce specific peptide substances, which could make these treatments more widely available. Hims & Hers had previously indicated to investors its interest in entering the peptide space, making this regulatory development a positive signal for its future business categories.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"HIMS","symbol_name":"Hims & Hers Health Inc.","start_time":0,"source_url":"","article_id":"1190132675","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1190132675","pubTimestamp":1776326750,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Hims & Hers Health Inc. (HIMS) experienced a significant pre-market surge of 10.66%, continuing its positive momentum from the previous trading session.The sharp rise appears driven by two major...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"HIMS":"Hims & Hers Health Inc."},"translate_title":"个股追踪|Hims&Hers Health盘前大涨10.66%受诺和诺德合作及FDA多肽监管审查影响","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HIMS":1},"content_text":"Hims & Hers Health Inc. (HIMS) experienced a significant pre-market surge of 10.66%, continuing its positive momentum from the previous trading session.The sharp rise appears driven by two major catalysts. First, the company has entered into a partnership with pharmaceutical giant Novo Nordisk, which will authorize the sale of Novo Nordisk's weight-loss drugs on the Hims platform. This marks a significant commercial milestone, expanding Hims' offerings in the high-demand weight management market.Secondly, U.S. regulators are moving forward with plans to reassess popular peptide treatments. The Food and Drug Administration has scheduled meetings to discuss whether certain pharmacies may be allowed to produce specific peptide substances, which could make these treatments more widely available. Hims & Hers had previously indicated to investors its interest in entering the peptide space, making this regulatory development a positive signal for its future business categories.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}